Nasdaq · CIK 0001789972
CGEM Cullinan Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 32 d ago. Close $15.53 on Oct 9, 2026, +120% from the 52-week low and -32% from the high.
Last 90 days
Net insider value
-$173k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$173k by 1 insider
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
CGEMOct 9, 2026 · close 15.53
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Cullinan Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Jennifer Michaelson Chief Scientific Officer sell | $173k 8,000 shares | -5% | +277% from low-5% from high | |
| 6Weak | Jennifer Michaelson Chief Scientific Officer sell | $125k 8,000 shares | -4% | +171% from low-4% from high | |
| 15Weak | Jennifer Michaelson Chief Scientific Officer sell | $25k 1,780 shares | -1% | +150% from low0% from high | |
| 52Moderate | Nadim Ahmed President and CEO sell | $196k 13,515 shares | -3% | +148% from low0% from high | |
| 37Weak | Jacquelyn L Sumer Chief Legal Officer sell | $52k 3,601 shares | -3% | +148% from low0% from high | |
| 38Weak | Jeffrey Alan Jones Chief Medical Officer sell | $66k 4,582 shares | -3% | +148% from low0% from high | |
| 18Weak | Jennifer Michaelson Chief Scientific Officer sell | $77k 5,353 shares | -3% | +143% from low0% from high | |
| 52Moderate | Nadim Ahmed President and CEO sell | $223k 16,381 shares | -4% | +137% from low-2% from high | |
| 37Weak | Jacquelyn L Sumer Chief Legal Officer sell | $51k 3,742 shares | -3% | +137% from low-2% from high | |
| 6Weak | Jennifer Michaelson Chief Scientific Officer sell | $165k 11,742 shares | -6% | +137% from low-2% from high | |
| 38Weak | Jeffrey Alan Jones Chief Medical Officer sell | $68k 4,982 shares | -3% | +137% from low-2% from high | |
| 44Moderate | Mary Kay Fenton Chief Financial Officer sell | $60k 4,398 shares | -3% | +137% from low-2% from high | |
| 30Weak | Jennifer Michaelson Chief Scientific Officer sell | $5,004 416 shares | -0% | +103% from low-12% from high | |
| 2Weak | Jennifer Michaelson Chief Scientific Officer sell | $49k 4,000 shares | -3% | +119% from low-3% from high | |
| 50Moderate | Nadim Ahmed President and CEO sell | $99k 9,922 shares | -2% | +74% from low-23% from high | |
| 10Weak | Jennifer Michaelson Chief Scientific Officer sell | $13k 1,345 shares | -1% | +68% from low-25% from high | |
| 35Weak | Jennifer Michaelson Chief Scientific Officer sell | $28k 2,898 shares | -2% | +74% from low-23% from high | |
| 36Weak | Jeffrey Alan Jones Chief Medical Officer sell | $45k 4,632 shares | -3% | +74% from low-23% from high | |
| 36Weak | Jacquelyn L Sumer Chief Legal Officer sell | $34k 3,480 shares | -3% | +74% from low-23% from high | |
| 16Weak | Jennifer Michaelson Chief Scientific Officer sell | $38k 3,143 shares | -2% | +107% from low-8% from high | |
| 2Weak | Jennifer Michaelson Chief Scientific Officer sell | $49k 4,000 shares | -3% | +125% from low-4% from high | |
| 45Moderate | Lynx1 Capital Management LP owner buy | $1.4M 165,667 shares | +2% | +48% from low-51% from high | |
| 45Moderate | Lynx1 Capital Management LP owner buy | $2.1M 248,749 shares | +3% | +35% from low-56% from high | |
| 46Moderate | Lynx1 Capital Management LP owner buy | $9.8M 1,459,641 shares | +21% | +12% from low-63% from high | |
| 50Moderate | Nadim Ahmed President and CEO sell | $107k 12,529 shares | -3% | 0% from low-53% from high | |
| 35Weak | Jacquelyn L Sumer Chief Legal Officer sell | $32k 3,756 shares | -3% | 0% from low-53% from high | |
| 35Weak | Jennifer Michaelson Chief Scientific Officer sell | $32k 3,756 shares | -3% | 0% from low-53% from high | |
| 36Weak | Jeffrey Alan Jones Chief Medical Officer sell | $42k 4,895 shares | -3% | 0% from low-53% from high | |
| 10Weak | Jennifer Michaelson Chief Scientific Officer sell | $50k 4,000 shares | -4% | +9% from low-35% from high | |
| 50Moderate | Nadim Ahmed President and CEO sell | $100k 8,400 shares | -3% | +14% from low-32% from high | |
| 36Weak | Jacquelyn L Sumer Chief Legal Officer sell | $40k 3,482 shares | -4% | - | |
| 37Weak | Jeffrey Alan Jones Chief Medical Officer sell | $53k 4,632 shares | -4% | - | |
| 37Weak | Jennifer Michaelson Chief Scientific Officer sell | $54k 4,693 shares | -4% | - | |
| 36Weak | Jennifer Michaelson Chief Scientific Officer sell | $44k 3,489 shares | -3% | - | |
| 6Weak | Jennifer Michaelson Chief Scientific Officer sell | $125k 8,000 shares | -7% | - |
Transactions
The last 77 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Jennifer Michaelson Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +4,000 | $4.30 | $17k | 166,844 | 32 d ago |
| Sep 8, 2026 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -8,000 | $21.57 | $173k | 158,844 | 32 d ago |
| Sep 8, 2026 | Jennifer Michaelson Chief Scientific Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,000 | $0.00 | $0 | 78,987 | 32 d ago |
| Mar 5, 2026 | Jennifer Michaelson Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +4,000 | $4.30 | $17k | 178,844 | Mar 9, 2026 |
| Mar 5, 2026 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -8,000 | $15.68 | $125k | 170,844 | Mar 9, 2026 |
| Mar 5, 2026 | Jennifer Michaelson Chief Scientific Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,000 | $0.00 | $0 | 120,987 | Mar 9, 2026 |
| Feb 25, 2026 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -1,780 | $14.14 | $25k | 174,844 | Feb 26, 2026 |
| Feb 24, 2026 | Nadim Ahmed President and CEO | SOpen-market sale Common Stock | -13,515 | $14.47 | $196k | 390,803 | Feb 25, 2026 |
| Feb 24, 2026 | Jacquelyn L Sumer Chief Legal Officer | SOpen-market sale Common Stock | -3,601 | $14.47 | $52k | 128,089 | Feb 25, 2026 |
| Feb 24, 2026 | Jeffrey Alan Jones Chief Medical Officer | SOpen-market sale Common Stock | -4,582 | $14.47 | $66k | 159,968 | Feb 25, 2026 |
| Feb 23, 2026 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -1,752 | $13.99 | $25k | 180,225 | Feb 25, 2026 |
| Feb 24, 2026 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -3,601 | $14.47 | $52k | 176,624 | Feb 25, 2026 |
| Feb 20, 2026 | Jacquelyn L Sumer Chief Legal Officer | SOpen-market sale Common Stock | -3,742 | $13.62 | $51k | 131,690 | Feb 23, 2026 |
| Feb 20, 2026 | Mary Kay Fenton Chief Financial Officer | SOpen-market sale Common Stock | -4,398 | $13.62 | $60k | 126,380 | Feb 23, 2026 |
| Feb 20, 2026 | Jeffrey Alan Jones Chief Medical Officer | SOpen-market sale Common Stock | -4,982 | $13.62 | $68k | 164,550 | Feb 23, 2026 |
| Feb 20, 2026 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -3,742 | $13.62 | $51k | 181,977 | Feb 23, 2026 |
| Feb 20, 2026 | Nadim Ahmed President and CEO | SOpen-market sale Common Stock | -16,381 | $13.62 | $223k | 404,318 | Feb 23, 2026 |
| Feb 20, 2026 | Jennifer Michaelson Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +8,000 | $4.30 | $34k | 189,977 | Feb 23, 2026 |
| Feb 20, 2026 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -8,000 | $14.30 | $114k | 181,977 | Feb 23, 2026 |
| Feb 20, 2026 | Jennifer Michaelson Chief Scientific Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,000 | $0.00 | $0 | 124,987 | Feb 23, 2026 |
| Feb 18, 2026 | Nadim Ahmed President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +828,000 | $0.00 | $0 | 828,000 | Feb 19, 2026 |
| Feb 18, 2026 | Jacquelyn L Sumer Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +230,000 | $0.00 | $0 | 230,000 | Feb 19, 2026 |
| Feb 18, 2026 | Jeffrey Alan Jones Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Feb 19, 2026 |
| Feb 18, 2026 | Corrine Savill Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Feb 19, 2026 |
| Feb 18, 2026 | Mary Kay Fenton Chief Financial Officer | AGrant or award Common Stock | +68,750 | $0.00 | $0 | 130,778 | Feb 19, 2026 |
| Feb 18, 2026 | Jennifer Michaelson Chief Scientific Officer | AGrant or award Common Stock | +57,500 | $0.00 | $0 | 185,719 | Feb 19, 2026 |
| Feb 18, 2026 | Mary Kay Fenton Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +137,500 | $0.00 | $0 | 137,500 | Feb 19, 2026 |
| Feb 18, 2026 | Jennifer Michaelson Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Feb 19, 2026 |
| Feb 12, 2026 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock | -416 | $12.03 | $5,004 | 128,219 | Feb 13, 2026 |
| Jan 22, 2026 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -4,000 | $12.30 | $49k | 128,635 | Jan 23, 2026 |
| Dec 31, 2025 | Mary Kay Fenton Chief Financial Officer | AGrant or award Common Stock | +27 | $6.49 | $175 | 62,028 | Jan 5, 2026 |
| Dec 23, 2025 | Nadim Ahmed President and CEO | SOpen-market sale Common Stock | -9,922 | $10.01 | $99k | 420,699 | Dec 29, 2025 |
| Dec 19, 2025 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -1,345 | $10.01 | $13k | 132,635 | Dec 22, 2025 |
| Dec 18, 2025 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock | -2,898 | $9.67 | $28k | 133,980 | Dec 19, 2025 |
| Dec 18, 2025 | Jeffrey Alan Jones Chief Medical Officer | SOpen-market sale Common Stock | -4,632 | $9.67 | $45k | 169,532 | Dec 19, 2025 |
| Dec 18, 2025 | Jacquelyn L Sumer Chief Legal Officer | SOpen-market sale Common Stock | -3,480 | $9.67 | $34k | 135,432 | Dec 19, 2025 |
| Dec 12, 2025 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -2,148 | $12.38 | $27k | 137,873 | Dec 16, 2025 |
| Dec 15, 2025 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -995 | $11.90 | $12k | 136,878 | Dec 16, 2025 |
| Nov 24, 2025 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -4,000 | $12.30 | $49k | 138,004 | Nov 25, 2025 |
| Oct 28, 2025 | Lynx1 Capital Management LP owner | POpen-market purchase Common stock, $0.0001 par value per shareindirect: See footnote | +165,667 | $8.40 | $1.4M | 8,963,500 | Oct 30, 2025 |
| Oct 14, 2025 | Lynx1 Capital Management LP owner | POpen-market purchase Common stock, $0.0001 par value per share ("Common Stock")indirect: See footnote | +15,032 | $7.59 | $114k | 8,564,116 | Oct 21, 2025 |
| Oct 15, 2025 | Lynx1 Capital Management LP owner | POpen-market purchase Common Stockindirect: See footnote | +51,500 | $7.94 | $409k | 8,615,616 | Oct 21, 2025 |
| Oct 16, 2025 | Lynx1 Capital Management LP owner | POpen-market purchase Common Stockindirect: See footnote | +150,000 | $8.86 | $1.3M | 8,765,616 | Oct 21, 2025 |
| Oct 17, 2025 | Lynx1 Capital Management LP owner | POpen-market purchase Common Stockindirect: See footnote | +32,217 | $7.84 | $253k | 8,797,833 | Oct 21, 2025 |
| Oct 8, 2025 | Lynx1 Capital Management LP owner | POpen-market purchase Common stock, $0.0001 par value per share ("Common Stock")indirect: See footnote | +556,300 | $6.46 | $3.6M | 7,645,743 | Oct 10, 2025 |
| Oct 9, 2025 | Lynx1 Capital Management LP owner | POpen-market purchase Common Stockindirect: See footnote | +626,043 | $6.70 | $4.2M | 8,271,786 | Oct 10, 2025 |
| Oct 10, 2025 | Lynx1 Capital Management LP owner | POpen-market purchase Common Stockindirect: See footnote | +277,298 | $7.36 | $2.0M | 8,549,084 | Oct 10, 2025 |
| Aug 7, 2025 | Andrew R Allen director | AGrant or award Stock Option (Right to Buy)derivative | +79,456 | $0.00 | $0 | 79,456 | Aug 8, 2025 |
| Aug 7, 2025 | Mittie Doyle director | AGrant or award Stock Option (Right to Buy)derivative | +79,456 | $0.00 | $0 | 79,456 | Aug 8, 2025 |
| Jun 12, 2025 | David D. Meek director | AGrant or award Stock Option (Right to Buy)derivative | +38,513 | $0.00 | $0 | 38,513 | Jun 16, 2025 |
| Jun 12, 2025 | David P. Ryan director | AGrant or award Stock Option (Right to Buy)derivative | +38,513 | $0.00 | $0 | 38,513 | Jun 16, 2025 |
| Jun 12, 2025 | Anthony Rosenberg director | AGrant or award Stock Option (Right to Buy)derivative | +38,513 | $0.00 | $0 | 38,513 | Jun 16, 2025 |
| Jun 12, 2025 | Stephen W Webster director | AGrant or award Stock Option (Right to Buy)derivative | +38,513 | $0.00 | $0 | 38,513 | Jun 16, 2025 |
| Jun 12, 2025 | Anne-Marie Martin director | AGrant or award Stock Option (Right to Buy)derivative | +38,513 | $0.00 | $0 | 38,513 | Jun 16, 2025 |
| Feb 25, 2025 | Nadim Ahmed President and CEO | SOpen-market sale Common Stock | -12,529 | $8.53 | $107k | 430,621 | Feb 27, 2025 |
| Feb 25, 2025 | Jacquelyn L Sumer Chief Legal Officer | SOpen-market sale Common Stock | -3,756 | $8.53 | $32k | 136,895 | Feb 27, 2025 |
| Feb 25, 2025 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock | -3,756 | $8.53 | $32k | 142,004 | Feb 27, 2025 |
| Feb 25, 2025 | Jeffrey Alan Jones Chief Medical Officer | SOpen-market sale Common Stock | -4,895 | $8.53 | $42k | 174,164 | Feb 27, 2025 |
| Feb 19, 2025 | Nadim Ahmed President and CEO | AGrant or award Common Stock | +180,000 | $0.00 | $0 | 443,150 | Feb 21, 2025 |
| Feb 19, 2025 | Jennifer Michaelson Chief Scientific Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 145,760 | Feb 21, 2025 |
| Feb 19, 2025 | Corrine Savill Chief Business Officer | AGrant or award Common Stock | +37,500 | $0.00 | $0 | 240,990 | Feb 21, 2025 |
| Feb 19, 2025 | Jacquelyn L Sumer Chief Legal Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 140,651 | Feb 21, 2025 |
| Feb 19, 2025 | Jeffrey Alan Jones Chief Medical Officer | AGrant or award Common Stock | +65,000 | $0.00 | $0 | 179,059 | Feb 21, 2025 |
| Feb 19, 2025 | Mary Kay Fenton Chief Financial Officer | AGrant or award Common Stock | +60,000 | $0.00 | $0 | 60,000 | Feb 21, 2025 |
| Feb 19, 2025 | Jeffrey Alan Jones Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +130,000 | $0.00 | $0 | 130,000 | Feb 21, 2025 |
| Feb 19, 2025 | Mary Kay Fenton Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Feb 21, 2025 |
| Feb 19, 2025 | Jacquelyn L Sumer Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 21, 2025 |
| Feb 19, 2025 | Corrine Savill Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Feb 21, 2025 |
| Feb 19, 2025 | Nadim Ahmed President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +360,000 | $0.00 | $0 | 360,000 | Feb 21, 2025 |
| Feb 19, 2025 | Jennifer Michaelson Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 21, 2025 |
| Jan 6, 2025 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -4,000 | $12.51 | $50k | 95,760 | Jan 7, 2025 |
| Dec 24, 2024 | Nadim Ahmed President and CEO | SOpen-market sale Common Stock | -8,400 | $11.87 | $100k | 263,150 | Dec 27, 2024 |
| Dec 18, 2024 | Jacquelyn L Sumer Chief Legal Officer | SOpen-market sale Common Stock | -3,482 | $11.41 | $40k | 90,651 | Dec 20, 2024 |
| Dec 18, 2024 | Jeffrey Alan Jones Chief Medical Officer | SOpen-market sale Common Stock | -4,632 | $11.41 | $53k | 114,059 | Dec 20, 2024 |
| Dec 18, 2024 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock | -4,693 | $11.41 | $54k | 99,760 | Dec 20, 2024 |
| Dec 12, 2024 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock | -3,489 | $12.52 | $44k | 104,453 | Dec 16, 2024 |
| Nov 5, 2024 | Jennifer Michaelson Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -8,000 | $15.64 | $125k | 107,942 | Nov 7, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Nadim AhmedPresident and CEO
- Andrew R Allendirector
- Mittie Doyleofficer, director
- Mary Kay FentonChief Financial Officer
- Jeffrey Alan JonesChief Medical Officer
- Lynx1 Capital Management LPowner
- Anne-Marie Martindirector
- David D. Meekdirector
- Jennifer MichaelsonChief Scientific Officer
- Anthony Rosenbergdirector
- David P. Ryandirector
- Jacquelyn L SumerChief Legal Officer
- Corrine SavillChief Business Officer
- Stephen W Websterdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.